Risk factors for the failure of antimuscarinic treatment with solifenacin in women with overactive bladder

Maurizio Serati, Andrea Braga, Gabriele Siesto, Paola Sorice, Elena Cattoni, Stefano Uccella, Antonella Cromi, Stefano Salvatore, Fabio Ghezzi

Research output: Contribution to journalArticlepeer-review


Objective To evaluate the outcomes of women treated with Solifenacin 5 mg once a day for overactive bladder (OAB) to identify the factors associated with the risk of treatment failure. Methods Women with OAB symptoms for at least 3 months were considered for this study. At visit 0, patients received a 3-day voiding diary. Eligibility was determined at visit 1, 2 weeks later, on the basis of the results recorded in the 3-day voiding diary. To be included, patients had to have experienced at least 3 episodes of urgency during the 3-day voiding diary period. Eligible women received a 12-week antimuscarinic therapy with oral Solifenacin 5 mg once a day. At the follow-up examination, objective outcomes included changes from baseline in the 3-day voiding diary data. Subjective efficacy was evaluated using the Overactive Bladder Questionnaire Short Form (OABq-SF), the Indevus urgency severity scale (USS) questionnaire, and the Patient Global Impression of Improvement. Results A total of 675 (69.3%) women met the inclusion criteria and were directed to Solifenacin therapy. After a 12-week treatment, 632 (93.6%) women were assessed for office evaluation, and 101 (16%) patients were considered as nonresponders. The antimuscarinics were effective both in terms of improvement of questionnaires scores and in terms of reduction of episodes of urgency/24 hour (P

Original languageEnglish
Pages (from-to)1044-1048
Number of pages5
Issue number5
Publication statusPublished - Nov 2013

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Risk factors for the failure of antimuscarinic treatment with solifenacin in women with overactive bladder'. Together they form a unique fingerprint.

Cite this